Based on the Allogene Therapeutics Inc stock forecast from 4 analysts, the average analyst target price for Allogene Therapeutics Inc is USD 7.75 over the next 12 months. Allogene Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Allogene Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Allogene Therapeutics Inc’s stock price was USD 1.45. Allogene Therapeutics Inc’s stock price has changed by +0.69% over the past week, -29.61% over the past month and -61.84% over the last year.
No recent analyst target price found for Allogene Therapeutics Inc
No recent average analyst rating found for Allogene Therapeutics Inc
Company Overview Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Read Less
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) ...Read More
Frequently Asked Questions About Allogene Therapeutics Inc (ALLO) Stock
Based on ratings from 4 analysts Allogene Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ALLO's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ALLO is USD 7.75 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on ALLO's stock to indicate if its overvalued.
The last closing price of ALLO's stock was USD 1.45.
The most recent market capitalization for ALLO is USD 0.46B.
Based on targets from 4 analysts, the average taret price for ALLO is projected at USD 7.75 over the next 12 months.
This means that ALLO's stock price may go up by +434.48% over the next 12 months.
We can't find any ETFs which contains Allogene Therapeutics Inc's stock.
As per our most recent records Allogene Therapeutics Inc has 232 Employees.
Allogene Therapeutics Inc's registered address is 210 East Grand Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from Allogene Therapeutics Inc's website at https://www.allogene.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Allogene Therapeutics Inc (ALLO) Stock
Based on ratings from 4 analysts Allogene Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ALLO's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ALLO is USD 7.75 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on ALLO's stock to indicate if its overvalued.
The last closing price of ALLO's stock was USD 1.45.
The most recent market capitalization for ALLO is USD 0.46B.
Based on targets from 4 analysts, the average taret price for ALLO is projected at USD 7.75 over the next 12 months.
This means that ALLO's stock price may go up by +434.48% over the next 12 months.
We can't find any ETFs which contains Allogene Therapeutics Inc's stock.
As per our most recent records Allogene Therapeutics Inc has 232 Employees.
Allogene Therapeutics Inc's registered address is 210 East Grand Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from Allogene Therapeutics Inc's website at https://www.allogene.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ALLO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
